½ºÇÁ¶óÀ̼¿ ½ÃÀå : Àα¸ µ¿Åº°, »çÀÌÄÚ±×·¡ÇȺ°, Çൿº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2023-2030³â)
Sprycel Market, By Demographic, By Psychographic, By Behavioral, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1401004
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

½ºÇÁ¶óÀ̼¿ ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 54¾ï 7,000¸¸ ´Þ·¯¸¦ ±â·ÏÇßÀ¸¸ç, 2023-2030³â CAGR 5.2%·Î È®´ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ºÇÁ¶óÀ̼¿ ½ÃÀå - ½ÃÀå ¿ªÇÐ

Ƽ·Î½Å Ű³ª¾ÆÁ¦·Î ¾Ë·ÁÁø ƯÁ¤ ¾Ï °ü·Ã ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â È¿´ÉÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù.

ȯÀÚÀÇ À¯ÀüÀû, ºÐÀÚÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ´Â Á¤¹ÐÀÇ·á´Â Ç¥Àû Ä¡·á¸¦ °¡Á®¿Ô½À´Ï´Ù. ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML)°ú Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´(Ph ALL) Ä¡·áÁ¦·Î °³¹ß ÁßÀÎ ´Ù»çƼ´ÕÀÌ ÀÌ ±â¼úÀÇ ÀÏ·ÊÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿Àº Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ È°¼ºÀ» °¨¼Ò½ÃÅ´À¸·Î½á ¾Ï¼¼Æ÷ÀÇ ¹ß»ýÀ» ÃËÁøÇÏ´Â ½ÅÈ£Àü´Þ °æ·Î¸¦ Â÷´ÜÇÏ¿© Ç¥ÁØ È­Çпä¹ýÀÇ ´ë¾ÈÀ¸·Î º¸´Ù È¿°úÀûÀÌ°í µ¶¼ºÀÌ ³·Àº Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù.

½ºÇÁ¶óÀ̼¿ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

AnalystView Market InsightsÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È ¸Å³â ¾à 5.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ºÇÁ¶óÀ̼¿ »ê¾÷Àº Ƽ·Î½Å Ű³ª¾ÆÁ¦·Î ¾Ë·ÁÁø ƯÁ¤ ¾Ï °ü·Ã ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â È¿°ú·Î ÀÎÇØ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àα¸Åë°èÇÐÀû ¼¼ºÐÈ­¿¡ µû¶ó 2022³â¿¡´Â ¿¬·Éº° ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 2022³â ¸ÅÃâ¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù.

½ºÇÁ¶óÀ̼¿ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀº Àα¸Åë°èÇÐÀû, ½É¸®ÇÐÀû, ÇൿÀû, Áö¿ªº°·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Àα¸ Åë°èÇп¡ µû¶ó ¿¬·É, ¼ºº°, ¼Òµæ µî ³× °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ¿¬·É ºÎ¹®ÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ½ºÇÁ¶óÀ̼¿(´Ù»çƼ´Õ)¿¡ ´ëÇÑ ¼ö¿ä´Â ³ëÀε鿡°Ô¼­ ¸¹ÀÌ ¹ß°ßµÇ´Â ƯÁ¤ À¯ÇüÀÇ ¹éÇ÷º´ Ä¡·á¿¡ »ç¿ëµÇ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML)°ú Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´(Ph ALL)Àº °í·ÉÃþ¿¡¼­ Á¡Á¡ ´õ ºó¹øÇÏ°Ô ¹ß»ýÇϰí ÀÖÀ¸¸ç, ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥ÀûÄ¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ½É¸®ÇÐÀû °üÁ¡¿¡¼­ »ýȰ½À°ü, ŵµÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. »ýȰ½À°ü ºÎ¹®Àº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿(´Ù»çƼ´Õ)ÀÇ »ýȰ½À°ü ¼ö¿ä´Â ÀϹÝÀûÀ¸·Î Ä¡·á¿¡ ¸ÂÃß¾î »ýȰ½À°üÀ» ¼öÁ¤ÇÏ´Â °ÍÀ¸·Î ±¸¼ºµË´Ï´Ù.

½ºÇÁ¶óÀ̼¿ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ³ª´¹´Ï´Ù. ÀÌ Áö¿ªµéÀº »ç¾÷ ¿î¿µ ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ºÇÁ¶óÀ̼¿(´Ù»çƼ´Õ) ¼ö¿ä´Â ´Ù¾çÇÑ º¯¼ö¿¡ ÀÇÇØ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ù°, Àα¸ Áõ°¡¿Í °í·ÉÈ­·Î ÀÎÇØ ¸¸¼º°ñ¼ö¼º¹éÇ÷º´(CML), Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´(Ph ALL)°ú °°Àº Ç÷¾× ¾Ç¼ºÁ¾¾ç ¹ß»ý ºóµµ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, ÀÇ·á ÀÎÇÁ¶ó¿Í Áø´Ü ±â¼úÀÇ ¹ßÀü, Çõ½ÅÀûÀÎ Ä¡·áÁ¦ÀÇ µîÀåÀ¸·Î Á¤±³ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ Àνİú ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Â°, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¦¾à ºÎ¹®°ú ¿¬±¸ ÆÄÆ®³Ê½ÊÀÌ È®´ëµÇ¸é¼­ ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥Àû Ä¡·áÁ¦°¡ ´õ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÀÌ Áö¿ª¿¡¼­ÀÇ È°¹ßÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, »ý¸íÀ» À§ÇùÇÏ´Â Áúº´À» ¾Î°í Àִ ȯÀڵ鿡°Ô Èñ¸ÁÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ºÇÁ¶óÀ̼¿ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ½ºÇÁ¶óÀ̼¿ »ê¾÷ Á¶»ç

Á¦5Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå ±¸µµ

Á¦7Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå : Àα¸ µ¿Åº°

Á¦8Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå : »çÀÌÄÚ±×·¡ÇȺ°

Á¦9Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå : Çൿº°

Á¦10Àå ½ºÇÁ¶óÀ̼¿ ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ½ºÇÁ¶óÀ̼¿ ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Sprycel Market size was valued at USD 5,470 Million in 2022, expanding at a CAGR of 5.2% from 2023 to 2030.

Sprycel (dasatinib) is a prescription drug used to treat some kinds of leukemia as well as other blood diseases. It belongs to the tyrosine kinase inhibitor family of medicines. Sprycel works by inhibiting the function of particular proteins involved in cancer cell proliferation and spread. This drug is used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). It is normally administered orally and plays an important role in treating certain hematologic malignancies, improving patient outcomes, and slowing disease progression.

Sprycel Market- Market Dynamics

Its efficacy in targeting specific cancer-related proteins, known as tyrosine kinases propel market demand

Precision medicine, which tailor's therapies based on a patient's genetic and molecular profile, has resulted in targeted therapy. Dasatinib, which is being developed as a therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), is an example of this technique. Sprycel interrupts the signaling pathways that drive cancer cell development by reducing the activity of tyrosine kinases, providing a more effective and less toxic alternative to standard chemotherapy and thereby improving the prognosis for patients with these illnesses.

Sprycel Market- Key Insights

As per the analysis shared by our research analyst, the global Sprycel market is estimated to grow annually at a CAGR of around 5.2% over the forecast period (2023-2030)

The Sprycel industry is projected to grow at a significant rate due to Its efficacy in targeting specific cancer-related proteins, known as tyrosine kinases.

Based on Demographic segmentation, Age was predicted to show maximum market share in the year 2022

Based on Psychographic segmentation, Lifestyle was the leading Demographic in 2022

On the basis of region, Asia Pacific was the leading revenue generator in 2022

Sprycel Market- Segmentation Analysis:

The Global Sprycel Market is segmented on the basis of Demographic, Psychographic, Behavioral, and Region.

The market is divided into four categories based on Demographic: Age, Gender, Income. The Age segment dominates the market. Sprycel (dasatinib) demand is largely driven by its usage in treating particular types of leukaemia that are more common in older persons. Chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) are becoming increasingly frequent in the elderly population, increasing need for targeted medicines such as Sprycel.

The market is divided into two categories based on Psychographic: Lifestyle, Attitudes. The Lifestyle sector dominates the market and is likely to maintain its dominance during the forecast period. Sprycel (dasatinib) lifestyle demand generally consists of people modifying their habits to accommodate therapy. To manage possible side effects, patients may need to stick to a regular prescription regimen and adopt dietary and exercise changes. While receiving Sprycel medication, lifestyle decisions that promote general well-being are often prioritized.

Sprycel Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Sprycel (dasatinib) demand in the Asia-Pacific area has been continuously growing due to a variety of variables. Owing to population expansion and aging, the area has seen an increase in the frequency of hematological malignancies such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Second, advances in healthcare infrastructure, diagnostics, and the availability of innovative therapeutics have increased awareness of and demand for sophisticated treatments. Third, the Asia-Pacific region's expanding pharmaceutical sector and research partnerships are making targeted medicines like Sprycel more accessible. These factors contribute to the region's strong demand for Sprycel, giving patients fighting these life-threatening illnesses hope.

Sprycel Market- Competitive Landscape:

Several main companies dominate the competitive landscape of tyrosine kinase inhibitors for hematological malignancies, including Sprycel (dasatinib). Sprycel's maker, Bristol Myers Squibb, has a substantial market share. However, competition comes from other pharmaceutical firms that manufacture comparable medications, such as imatinib and nilotinib. Competition is aided by ongoing research efforts to create more effective and focused medicines in this class. Furthermore, generic versions of these drugs have an impact on the landscape by offering patients with more cost choices. The competitive environment encourages innovation and guarantees that patients with leukaemia and associated illnesses have access to a variety of treatment alternatives.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SPRYCEL MARKET KEY PLAYERS

GLOBAL SPRYCEL MARKET, BY DEMOGRAPHIC

GLOBAL SPRYCEL MARKET, BY PSYCHOGRAPHIC

GLOBAL SPRYCEL MARKET, BY BEHAVIORAL

GLOBAL SPRYCEL MARKET, BY REGION

Table of Contents

1. Sprycel Market Overview

2. Executive Summary

3. Sprycel Key Market Trends

4. Sprycel Industry Study

5. Sprycel Market: COVID-19 Impact Analysis

6. Sprycel Market Landscape

7. Sprycel Market - By Demographic

8. Sprycel Market - By Psychographic

9. Sprycel Market - By Behavioral

10. Sprycel Market- By Geography

11. Key Vendor Analysis- Sprycel Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â